Primer | Published:

REM sleep behaviour disorder

Nature Reviews Disease Primersvolume 4, Article number: 19 (2018) | Download Citation

Abstract

Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia that is characterized by loss of muscle atonia during REM sleep (known as REM sleep without atonia, or RSWA) and abnormal behaviours occurring during REM sleep, often as dream enactments that can cause injury. RBD is categorized as either idiopathic RBD or symptomatic (also known as secondary) RBD; the latter is associated with antidepressant use or with neurological diseases, especially α-synucleinopathies (such as Parkinson disease, dementia with Lewy bodies and multiple system atrophy) but also narcolepsy type 1. A clinical history of dream enactment or complex motor behaviours together with the presence of muscle activity during REM sleep confirmed by video polysomnography are mandatory for a definite RBD diagnosis. Management involves clonazepam and/or melatonin and counselling and aims to suppress unpleasant dreams and behaviours and improve bedpartner quality of life. RSWA and RBD are now recognized as manifestations of an α-synucleinopathy; most older adults with idiopathic RBD will eventually develop an overt neurodegenerative syndrome. In the future, studies will likely evaluate neuroprotective therapies in patients with idiopathic RBD to prevent or delay α-synucleinopathy-related motor and cognitive decline.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Sateia, M. J. International classification of sleep disorders.Third edition (ICSD-3). Chest 146, 1387–1394 (2014).

  2. 2.

    Frauscher, B. et al. Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep 35, 835–847 (2012). This study presents the best PSG normative values for the correct diagnosis of RBD for clinical practice.

  3. 3.

    Schenck, C. H., Högl, B. & Videnovic, A. Rapid-Eye-movement Sleep Behavior Disorder (Springer, 2018).

  4. 4.

    Frauscher, B. et al. Video analysis of motor events in REM sleep behavior disorder. Mov. Disord. 22, 1464–1470 (2007).

  5. 5.

    Frauscher, B., Ehrmann, L. & Högl, B. Defining muscle activities for assessment of rapid eye movement sleep behavior disorder: from a qualitative to a quantitative diagnostic level. Sleep Med. 14, 729–733 (2013).

  6. 6.

    Boeve, B. F. REM sleep behavior disorder: updated review of the core features, the RBD-Neurodegenerative Disease Association, evolving concepts, controversies, and future directions. Ann. NY Acad. Sci. 1184, 15–54 (2010).

  7. 7.

    Olson, E. J., Boeve, B. F. & Silber, M. H. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 123, 331–339 (2000). This article provides a comprehensive assessment of demographic, clinical and laboratory findings and management strategies of patients with iRBD.

  8. 8.

    Iranzo, A., Santamaria, J. & Tolosa, E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol. 15, 405–419 (2016).

  9. 9.

    Fernández-Arcos, A., Iranzo, A., Serradell, M., Gaig, C. & Santamaria, J. The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation: a study in 203 consecutive patients. Sleep 39, 121–132 (2016).

  10. 10.

    Schenck, C. H. & Mahowald, M. W. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in sleep. Sleep 25, 120–138 (2002).

  11. 11.

    Castelnovo, A., Lopez, R., Proserpio, P., Nobili, L. & Dauvilliers, Y. NREM sleep parasomnias as disorders of sleep-state dissociation. Nat. Rev. Neurol. https://doi.org/10.1038/s41582-018-0030-y (2018). This article provides a comprehensive review on clinical, neurophysiological, biological aspects and management of NREM parasomnia.

  12. 12.

    Postuma, R. B. et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72, 1296–1300 (2009).

  13. 13.

    Claassen, D. O. et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 75, 494–499 (2010).

  14. 14.

    Boot, B. P. et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann. Neurol. 71, 49–56 (2012).

  15. 15.

    Wong, J. C. et al. Risk factors for probable REM sleep behavior disorder: a community-based study. Neurology 86, 1306–1312 (2016).

  16. 16.

    Ma, J. et al. A community-based study of risk factors for probable rapid eye movement sleep behavior disorder. Sleep Med. 30, 71–76 (2017).

  17. 17.

    Ma, C. et al. Probable REM sleep behavior disorder and risk of stroke: a prospective study. Neurology 88, 1849–1855 (2017).

  18. 18.

    Mahlknecht, P. et al. Probable RBD and association with neurodegenerative disease markers: a population-based study. Mov. Disord. 30, 1417–1421 (2015).

  19. 19.

    Kang, S. et al. REM sleep behavior disorder in the Korean elderly population: prevalence and clinical characteristics. Sleep 36, 1147–1152 (2013).

  20. 20.

    Haba-Rubio, J. et al. Prevalence and determinants of REM sleep behavior disorder in the general population. Sleep 41, zsx197 (2017). This is one of the most important epidemiological studies in a middle-to-older age population-based sample showing a prevalence of RBD at 1.06%, with no difference between men and women.

  21. 21.

    Pujol, M. et al. Idiopathic REM sleep behavior disorder in the elderly Spanish community: a primary care center study with a two-stage design using video-polysomnography. Sleep Med. 40, 116–121 (2017).

  22. 22.

    Mayer, G. & Meier-Ewert, K. Motor dyscontrol in sleep of narcoleptic patients (a lifelong development?). J. Sleep Res. 2, 143–148 (1993).

  23. 23.

    Dauvilliers, Y. et al. REM sleep characteristics in narcolepsy and REM sleep behavior disorder. Sleep 30, 844–849 (2007). This is one of the first studies to demonstrate abnormalities in REM sleep motor regulation with an increased frequency of RSWA in narcolepsy.

  24. 24.

    Teman, P. T., Tippmann-Peikert, M., Silber, M. H., Slocumb, N. L. & Auger, R. R. Idiopathic rapid-eye-movement sleep disorder: associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. Sleep Med. 10, 60–65 (2009).

  25. 25.

    McCarter, S. J. et al. Antidepressants increase REM sleep muscle tone in patients with and without REM sleep behavior disorder. Sleep 38, 907–917 (2015).

  26. 26.

    Postuma, R. B. et al. Environmental risk factors for REM sleep behavior disorder A multicenter case-control study. Neurology 79, 428–434 (2012). This is the first multicentre case–control study to assess environmental and lifestyle risk factors for RBD.

  27. 27.

    Ferini-Strambi, L. et al. Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case–control study. J. Neurol. 261, 1112–1118 (2014).

  28. 28.

    Frauscher, B. et al. Comorbidity and medication in REM sleep behavior disorder A multicenter case-control study. Neurology 82, 1076–1079 (2014).

  29. 29.

    Dauvilliers, Y. et al. Family history of idiopathic REM behavior disorder: a multicenter case-control study. Neurology 80, 2233–2235 (2013).

  30. 30.

    Ascherio, A. & Schwarzschild, M. A. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 15, 1257–1272 (2016).

  31. 31.

    Gan-Or, Z. et al. GBA mutations are associated with rapid eye movement sleep behavior disorder. Ann. Clin. Transl Neurol. 2, 941–945 (2015).

  32. 32.

    Gan-Or, Z. et al. Heterozygous PINK1 p. G411S in rapid eye movement sleep behaviour disorder. Brain 140, e32–e32 (2017).

  33. 33.

    Pont-Sunyer, C. et al. Sleep disorders in parkinsonian and nonparkinsonian LRRK2 mutation carriers. PLoS ONE 10, e0132368 (2015).

  34. 34.

    Fernández-Santiago, R. et al. Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder. Neurology 86, 1072–1073 (2016).

  35. 35.

    Gan-Or, Z. et al. The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder. Neurobiol. Aging 49, 218–e213 (2017).

  36. 36.

    Schenck, C. H., Bundlie, S. R. & Mahowald, M. W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 46, 388–393 (1996).

  37. 37.

    Schenck, C. H., Boeve, B. F. & Mahowald, M. W. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 14, 744–748 (2013). This is the first cohort study showing that RBD can be a heralding manifestation of PD.

  38. 38.

    Iranzo, A. et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 5, 572–577 (2006).

  39. 39.

    Iranzo, A. et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS ONE 9, e89741 (2014).

  40. 40.

    Iranzo, A. et al. Characterization of patients with longstanding idiopathic REM sleep behavior disorder. Neurology 89, 242–248 (2017).

  41. 41.

    Wing, Y. K. et al. Prospective outcome of rapid eye movement sleep behaviour disorder: psychiatric disorders as a potential early marker of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 83, 470–472 (2012).

  42. 42.

    Arnulf, I. et al. Sleepiness in idiopathic REM sleep behavior disorder and Parkinson disease. Sleep 38, 1529–1535 (2015).

  43. 43.

    Mahlknecht, P. et al. Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 84, 654–658 (2015).

  44. 44.

    Li, Y. et al. Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. Neurology 88, 1493–1500 (2017).

  45. 45.

    Zhou, J. et al. Excessive daytime sleepiness predicts neurodegeneration in idiopathic REM sleep behavior disorder. Sleep 40, zsx041 (2017).

  46. 46.

    Postuma, R. B. et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann. Neurol. 77, 830–839 (2015). This is the first multicentre study showing that patients with iRBD are at very high risk of neurodegenerative α-synucleinopathy with different risk factor profiles between converters and nonconverters.

  47. 47.

    George, R., Haslett, W. L. & Jenden, D. J. A cholinergic mechanism in the brainstem reticular formation: induction of paradoxical sleep. Int. J. Neuropharmacol. 3, 541–552 (1964).

  48. 48.

    Jouvet, M. & Delorme, F. Locus coeruleus et sommeil paradoxal. C. R. Seances Soc. Biol. Fil. 159, 895–899 (1965). This study presents the first animal model of RBD, described 21 years before the formal description of RBD in humans.

  49. 49.

    Jouvet, M. Recherches sur les structures nerveuses et les mécanismes responsables des différentes phases du sommeil physiologique. Arch. Ital. Biol. 100, 125–206 (1962).

  50. 50.

    Schenck, C. H., Bundlie, S. R., Ettinger, M. G. & Mahowald, M. W. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 9, 293–308 (1986). This study reports the first formal clinical description of a new category of parasomnia: the RBD.

  51. 51.

    Aston-Jones, G. & Bloom, F. E. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J. Neurosci. 1, 876–886 (1981).

  52. 52.

    Boucetta, S., Cissé, Y., Mainville, L., Morales, M. & Jones, B. E. Discharge profiles across the sleep-waking cycle of identified cholinergic, GABAergic, and glutamatergic neurons in the pontomesencephalic tegmentum of the rat. J. Neurosci. 34, 4708–4727 (2014).

  53. 53.

    Lu, J., Sherman, D., Devor, M. & Saper, C. B. A putative flip-flop switch for control of REM sleep. Nature 441, 589–594 (2006).

  54. 54.

    Clément, O., Sapin, E., Bérod, A., Fort, P. & Luppi, P. Evidence that neurons of the sublaterodorsal tegmental nucleus triggering paradoxical (REM) sleep are glutamatergic. Sleep 34, 419–423 (2011).

  55. 55.

    Valencia Garcia, S. et al. Genetic inactivation of glutamate neurons in the rat sublaterodorsal tegmental nucleus recapitulates REM sleep behaviour disorder. Brain 140, 414–428 (2016). This study describes an animal model of RBD that has behaviours during REM sleep that mimic human RBD.

  56. 56.

    Krenzer, M. et al. Brainstem and spinal cord circuitry regulating REM sleep and muscle atonia. PLoS ONE 6, e24998 (2011).

  57. 57.

    Ehrminger, M. et al. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain 139, 1180–1188 (2016).

  58. 58.

    Iranzo, A., Santamaria, J. & Tolosa, E. The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Med. Rev. 13, 385–401 (2009).

  59. 59.

    Boissard, R. et al. The rat ponto-medullary network responsible for paradoxical sleep onset and maintenance: a combined microinjection and functional neuroanatomical study. Eur. J. Neurosci. 16, 1959–1973 (2002).

  60. 60.

    Sapin, E. et al. Localization of the brainstem GABAergic neurons controlling paradoxical (REM) sleep. PLoS ONE 4, e4272 (2009).

  61. 61.

    Chase, M. H., Soja, P. J. & Morales, F. R. Evidence that glycine mediates the postsynaptic potentials that inhibit lumbar motoneurons during the atonia of active sleep. J. Neurosci. 9, 743–751 (1989).

  62. 62.

    Brooks, P. L. & Peever, J. H. Identification of the transmitter and receptor mechanisms responsible for REM sleep paralysis. J. Neurosci. 32, 9785–9795 (2012).

  63. 63.

    Holmes, C. J. & Jones, B. E. Importance of cholinergic, GABAergic, serotonergic and other neurons in the medial medullary reticular formation for sleep-wake states studied by cytotoxic lesions in the cat. Neuroscience 62, 1179–1200 (1994).

  64. 64.

    Limousin, N. et al. A brainstem inflammatory lesion causing REM sleep behavior disorder and sleepwalking (parasomnia overlap disorder). Sleep Med. 10, 1059–1062 (2009).

  65. 65.

    Iranzo, A. et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 12, 443–453 (2013). A key cohort study showing that most patients with iRBD developed a Lewy body disorder such as PD or DLB with time.

  66. 66.

    Boeve, B. F. et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med. 8, 60–64 (2007).

  67. 67.

    Arnulf, I. REM sleep behavior disorder: motor manifestations and pathophysiology. Mov. Disord. 27, 677–689 (2012).

  68. 68.

    Hayashi, Y. et al. Cells of a common developmental origin regulate REM/non-REM sleep and wakefulness in mice. Science 350, 957–961 (2015).

  69. 69.

    Burgess, C., Lai, D., Siegel, J. & Peever, J. H. An endogenous glutamatergic drive onto somatic motoneurons contributes to the stereotypical pattern of muscle tone across the sleep–wake cycle. J. Neurosci. 28, 4649–4660 (2008).

  70. 70.

    Rekling, J. C., Funk, G. D., Bayliss, D. A., Dong, X. & Feldman, J. L. Synaptic control of motoneuronal excitability. Physiol. Rev. 80, 767–852 (2000).

  71. 71.

    De Cock, V. et al. Restoration of normal motor control in Parkinson’s disease during REM sleep. Brain 130, 450–456 (2007).

  72. 72.

    De Carli, F. et al. Activation of the motor cortex during phasic rapid eye movement sleep. Ann. Neurol. 79, 326–330 (2016).

  73. 73.

    Mayer, G., Bitterlich, M., Kuwert, T., Ritt, P. & Stefan, H. Ictal SPECT in patients with rapid eye movement sleep behaviour disorder. Brain 138, 1263–1270 (2015).

  74. 74.

    Dauvilliers, Y. & Peigneux, P. Ictal SPECT in patients with rapid eye movement sleep behaviour disorder. Brain 138, e390–e390 (2015).

  75. 75.

    Dauvilliers, Y. et al. Increased perfusion in supplementary motor area during a REM sleep behaviour episode. Sleep Med. 12, 531–532 (2011).

  76. 76.

    Del Rio-Bermudez, C., Sokoloff, G. & Blumberg, M. S. Sensorimotor processing in the newborn rat red nucleus during active sleep. J. Neurosci. 35, 8322–8332 (2015).

  77. 77.

    Blumberg, M. S. & Plumeau, A. M. A new view of “dream enactment” in REM sleep behavior disorder. Sleep Med. Rev. 30, 34–42 (2016).

  78. 78.

    Dauvilliers, Y., Jennum, P. & Plazzi, G. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Med. 14, 775–781 (2013).

  79. 79.

    Cipolli, C., Franceschini, C., Mattarozzi, K., Mazzetti, M. & Plazzi, G. Overnight distribution and motor characteristics of REM sleep behaviour disorder episodes in patients with narcolepsy–cataplexy. Sleep Med. 12, 635–640 (2011).

  80. 80.

    Franceschini, C. et al. Motor events during REM sleep in patients with narcolepsy–cataplexy: a video-polysomnographic pilot study. Sleep Med. 12, S59–S63 (2011).

  81. 81.

    Mileykovskiy, B. Y., Kiyashchenko, L. I. & Siegel, J. M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 46, 787–798 (2005).

  82. 82.

    Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 318, 121–134 (2004).

  83. 83.

    Hansen, C. et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715–725 (2011).

  84. 84.

    Luk, K. C. et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209, 975–986 (2012).

  85. 85.

    Oudiette, D. et al. Nonviolent elaborate behaviors may also occur in REM sleep behavior disorder. Neurology 72, 551–557 (2009).

  86. 86.

    Fantini, M. L., Corona, A., Clerici, S. & Ferini-Strambi, L. Aggressive dream content without daytime aggressiveness in REM sleep behavior disorder. Neurology 65, 1010–1015 (2005).

  87. 87.

    Uguccioni, G. et al. Fight or flight? Dream content during sleepwalking/sleep terrors versus rapid eye movement sleep behavior disorder. Sleep Med. 14, 391–398 (2013).

  88. 88.

    Montplaisir, J., Zadra, A., Nielsen, T. & Petit, D. in Sleep Disorders Medicine 1087–1113 (Springer, 2017).

  89. 89.

    Valli, K. et al. Dreaming furiously? A sleep laboratory study on the dream content of people with Parkinson’s disease and with or without rapid eye movement sleep behavior disorder. Sleep Med. 16, 419–427 (2015).

  90. 90.

    Schenck, C. H., Lee, S. A., Bornemann, M. A. C. & Mahowald, M. W. Potentially lethal behaviors associated with rapid eye movement sleep behavior disorder: review of the literature and forensic implications. J. Forensic Sci. 54, 1475–1484 (2009).

  91. 91.

    Zhang, J. et al. Diagnosis of REM sleep behavior disorder by video-polysomnographic study: is one night enough? Sleep 31, 1179–1185 (2008).

  92. 92.

    Lapierre, O. & Montplaisir, J. Polysomnographic features of REM sleep behavior disorder development of a scoring method. Neurology 42, 1371 (1992).

  93. 93.

    Montplaisir, J. et al. Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. Mov. Disord. 25, 2044–2051 (2010). This is one of the first validated PSG studies to estimate the diagnostic value of a visual scoring method for the diagnosis of iRBD with establishment of cut-off values to be used in clinical and research settings.

  94. 94.

    McGrane, I. R., Leung, J. G., St Louis, E. K. & Boeve, B. F. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 16, 19–26 (2015).

  95. 95.

    Ferri, R. et al. A quantitative statistical analysis of the submentalis muscle EMG amplitude during sleep in normal controls and patients with REM sleep behavior disorder. J. Sleep Res. 17, 89–100 (2008).

  96. 96.

    Mayer, G. et al. Quantification of tonic and phasic muscle activity in REM sleep behavior disorder. J. Clin. Neurophysiol. 25, 48–55 (2008).

  97. 97.

    Ferri, R., Gagnon, J., Postuma, R. B., Rundo, F. & Montplaisir, J. Y. Comparison between an automatic and a visual scoring method of the chin muscle tone during rapid eye movement sleep. Sleep Med. 15, 661–665 (2014).

  98. 98.

    Frauscher, B. et al. Validation of an integrated software for the detection of rapid eye movement sleep behavior disorder. Sleep 37, 1663–1671 (2014).

  99. 99.

    Frandsen, R., Nikolic, M., Zoetmulder, M., Kempfner, L. & Jennum, P. Analysis of automated quantification of motor activity in REM sleep behaviour disorder. J. Sleep Res. 24, 583–590 (2015).

  100. 100.

    Figorilli, M. et al. Comparison between automatic and visual scorings of REM sleep without atonia for the diagnosis of REM sleep behavior disorder in Parkinson disease. Sleep 40, zsw060 (2017).

  101. 101.

    Kempfner, J., Sorensen, G., Zoetmulder, M., Jennum, P. & Sorensen, H. B. REM behaviour disorder detection associated with neurodegenerative diseases. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2010, 5093–5096 (2010).

  102. 102.

    Guttowski, D., Mayer, G., Oertel, W. H., Kesper, K. & Rosenberg, T. Validation of semiautomatic scoring of REM sleep without atonia in patients with RBD. Sleep Med. 46, 107–113 (2018).

  103. 103.

    Ferri, R., Fantini, M. L. & Schenck, C. H. The role of REM sleep without atonia in the diagnosis of REM sleep behavior disorder: past errors and new challenges. Sleep Med. 15, 1007–1008 (2014).

  104. 104.

    Stefani, A. et al. Long-term follow-up investigation of isolated rapid eye movement sleep without atonia without rapid eye movement sleep behavior disorder: a pilot study. J. Clin. Sleep Med. JCSM Off. Publ. Am. Acad. Sleep Med. 11, 1273–1279 (2015).

  105. 105.

    Sixel-Döring, F., Trautmann, E., Mollenhauer, B. & Trenkwalder, C. Rapid eye movement sleep behavioral events: a new marker for neurodegeneration in early Parkinson disease? Sleep 37, 431–438 (2014).

  106. 106.

    Fantini, M. L., Michaud, M., Gosselin, N., Lavigne, G. & Montplaisir, J. Periodic leg movements in REM sleep behavior disorder and related autonomic and EEG activation. Neurology 59, 1889–1894 (2002).

  107. 107.

    Manconi, M. et al. Time structure analysis of leg movements during sleep in REM sleep behavior disorder. Sleep 30, 1779–1785 (2007).

  108. 108.

    Iranzo, A. & Santamaría, J. Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep 28, 203–206 (2005).

  109. 109.

    Gaig, C., Iranzo, A., Pujol, M., Perez, H. & Santamaria, J. Periodic limb movements during sleep mimicking REM sleep behavior disorder: a new form of periodic limb movement disorder. Sleep 40, zsw063 (2016).

  110. 110.

    Vignatelli, L. et al. Prevalence of sleep-related hypermotor epilepsy — formerly named nocturnal frontal lobe epilepsy — in the adult population of the Emilia-Romagna Region, Italy. Sleep 40, zsw041 (2017).

  111. 111.

    Bugalho, P., Mendonça, M., Barbosa, R. & Salavisa, M. The influence of sleep disordered breathing in REM sleep behavior disorder. Sleep Med. 37, 210–215 (2017).

  112. 112.

    Zadra, A., Desautels, A., Petit, D. & Montplaisir, J. Somnambulism: clinical aspects and pathophysiological hypotheses. Lancet Neurol. 12, 285–294 (2013).

  113. 113.

    Lopez, R. et al. Diagnostic criteria for disorders of arousal: a video-polysomnography assessment. Ann. Neurol. 83, 341–351 (2018).

  114. 114.

    Oudiette, D. et al. Dreamlike mentations during sleepwalking and sleep terrors in adults. Sleep 32, 1621–1627 (2009).

  115. 115.

    Antelmi, E. et al. From state dissociation to status dissociatus. Sleep Med. Rev. 28, 1–13 (2016).

  116. 116.

    Mysliwiec, V. et al. Trauma associated sleep disorder: a proposed parasomnia encompassing disruptive nocturnal behaviors, nightmares, and REM without atonia in trauma survivors. J. Clin. Sleep Med. 10, 1143–1148 (2014).

  117. 117.

    Neikrug, A. B. & Ancoli-Israel, S. Diagnostic tools for REM sleep behavior disorder. Sleep Med. Rev. 16, 415–429 (2012).

  118. 118.

    Stiasny-Kolster, K. et al. The REM sleep behavior disorder screening questionnaire — a new diagnostic instrument. Mov. Disord. 22, 2386–2393 (2007).

  119. 119.

    Li, K., Li, S.-H., Su, W. & Chen, H.-B. Diagnostic accuracy of REM sleep behaviour disorder screening questionnaire: a meta-analysis. Neurol. Sci. 38, 1039–1046 (2017).

  120. 120.

    Halsband, C., Zapf, A., Sixel-Döring, F., Trenkwalder, C. & Mollenhauer, B. The REM sleep behavior disorder screening questionnaire is not valid in de novo Parkinson’s disease. Mov. Disord. Clin. Pract. 5, 171–176 (2018).

  121. 121.

    Li, S. X. et al. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK). Sleep Med. 11, 43–48 (2010).

  122. 122.

    Frauscher, B. et al. Validation of the Innsbruck REM sleep behavior disorder inventory. Mov. Disord. 27, 1673–1678 (2012).

  123. 123.

    Postuma, R. B. et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov. Disord. 27, 913–916 (2012).

  124. 124.

    Boeve, B. F. et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J. Clin. Sleep Med. 9, 475–480 (2013).

  125. 125.

    Aurora, R. N. et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J. Clin. Sleep Med. 6, 85 (2010).

  126. 126.

    Schenck, C. H., Hurwitz, T. D. & Mahowald, M. W. REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. J. Sleep Res. 2, 224–231 (1993).

  127. 127.

    Schenck, C. H. et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy — a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med. 14, 795–806 (2013).

  128. 128.

    Boeve, B. F. Update on the diagnosis and management of sleep disturbances in dementia. Sleep Med. Clin. 3, 347–360 (2008).

  129. 129.

    Ho, B. & Iranzo, A. Rapid eye movement sleep behavior disorder and other rapid eye movement sleep parasomnias. Continuum 23, 1017–1034 (2017).

  130. 130.

    Schenck, C. H. Paradox Lost: Midnight in the Battleground of Sleep and Dreams: “Violent Moving Nightmares” schen010@umn.edu (Extreme-Nights, LLC, Minneapolis, MN, 2005).

  131. 131.

    Hauri, P., Silber, M. & Boeve, B. The treatment of parasomnias with hypnosis: a 5-year follow-up study. J. Clin. Sleep Med. 3, 369–373 (2007).

  132. 132.

    Howell, M. J., Arneson, P. A. & Schenck, C. H. A novel therapy for REM sleep behavior disorder (RBD). J. Clin. Sleep Med. 7, 639 (2011).

  133. 133.

    Onofrj, M., Luciano, A. L., Thomas, A., Iacono, D. & d’Andreamatteo, G. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 60, 113–115 (2003).

  134. 134.

    Winkelman, J. W. & James, L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 27, 317–321 (2004).

  135. 135.

    Iranzo, A. & Santamaria, J. Bisoprolol-induced rapid eye movement sleep behavior disorder. Am. J. Med. 107, 390–392 (1999).

  136. 136.

    Schenck, C. & Mahowald, M. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am. J. Med. 100, 333–337 (1996).

  137. 137.

    Jung, Y. & St Louis, E. K. Treatment of REM sleep behavior disorder. Curr. Treat. Opt. Neurol. 18, 50 (2016).

  138. 138.

    Li, S. X. et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 21, 114–120 (2016).

  139. 139.

    McCarter, S. J. et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 14, 237–242 (2013).

  140. 140.

    Kunz, D. & Bes, F. Melatonin as a therapy in rem sleep behavior disorder patients: An open-labeled pilot study on the possible influence of melatonin on rem-sleep regulation. Mov. Disord. 14, 507–511 (1999).

  141. 141.

    Boeve, B. F., Silber, M. H. & Ferman, T. J. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 4, 281–284 (2003).

  142. 142.

    Schaefer, C., Kunz, D. & Bes, F. Melatonin effects in REM sleep behavior disorder associated with obstructive sleep apnea syndrome: a case series. Curr. Alzheimer Res. 14, 1084–1089 (2017).

  143. 143.

    Fantini, M. L., Gagnon, J., Filipini, D. & Montplaisir, J. Y. The effects of pramipexole in REM sleep behavior disorder. Neurology 61, 1418–1420 (2003).

  144. 144.

    Wang, Y. et al. Effects of rotigotine on REM sleep behavior disorder in Parkinson disease. J. Clin. Sleep Med. 12, 1403 (2016).

  145. 145.

    Ringman, J. M. & Simmons, J. H. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 55, 870–871 (2000).

  146. 146.

    Brunetti, V. et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr. Alzheimer Res. 11, 267–273 (2014).

  147. 147.

    Di Giacopo, R. et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov. Disord. 27, 559–561 (2012).

  148. 148.

    Bamford, C. R. Carbamazepine in REM sleep behavior disorder. Sleep 16, 33–34 (1993).

  149. 149.

    Moghadam, K. K., Pizza, F., Primavera, A., Ferri, R. & Plazzi, G. Sodium oxybate for idiopathic REM sleep behavior disorder: a report on two patients. Sleep Med. 32, 16–21 (2017).

  150. 150.

    Nomura, T., Kawase, S., Watanabe, Y. & Nakashima, K. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern. Med. 52, 2123–2126 (2013).

  151. 151.

    Mahowald, M. W., Schenck, C. H., Goldner, M., Bachelder, V. & Cramer-Bornemann, M. Parasomnia pseudo-suicide. J. Forensic Sci. 48, 1158–1162 (2003).

  152. 152.

    Mahowald, M. W., Bundlie, S. R., Hurwitz, T. D. & Schenck, C. H. Sleep violence — forensic science implications: polygraphic and video documentation. J. Forensic Sci. 35, 413–432 (1990).

  153. 153.

    Ingravallo, F., Schenck, C. H. & Plazzi, G. Injurious REM sleep behaviour disorder in narcolepsy with cataplexy contributing to criminal proceedings and divorce. Sleep Med. 11, 950–952 (2010).

  154. 154.

    Yeh, S.-B. & Schenck, C. H. A case of marital discord and secondary depression with attempted suicide resulting from REM sleep behavior disorder in a 35-year-old woman. Sleep Med. 5, 151–154 (2004).

  155. 155.

    Lam, S. P. et al. Caring burden of REM sleep behavior disorder–spouses’ health and marital relationship. Sleep Med. 24, 40–43 (2016).

  156. 156.

    Rolinski, M. et al. REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 85, 560–566 (2014).

  157. 157.

    Suzuki, K. et al. Probable rapid eye movement sleep behavior disorder, nocturnal disturbances and quality of life in patients with Parkinson’s disease: a case-controlled study using the rapid eye movement sleep behavior disorder screening questionnaire. BMC Neurol. 13, 18 (2013).

  158. 158.

    Neikrug, A. B. et al. Parkinson’s disease and REM sleep behavior disorder result in increased non-motor symptoms. Sleep Med. 15, 959–966 (2014).

  159. 159.

    Dyken, M. E., Lin-Dyken, D. C., Seaba, P. & Yamada, T. Violent sleep-related behavior leading to subdural hemorrhage. Arch. Neurol. 52, 318–321 (1995).

  160. 160.

    McCarter, S. J. et al. Factors associated with injury in REM sleep behavior disorder. Sleep Med. 15, 1332–1338 (2014).

  161. 161.

    Ramos-Campoy, O., Gaig, C., Villas, M., Iranzo, A. & Santamaria, J. REM sleep behavior disorder causing subdural hematoma. Sleep Med. 30, 43–44 (2017).

  162. 162.

    Zhou, J., Liang, B., Du, L., Tan, L. & Tang, X. A patient with childhood-onset aggressive parasomnia diagnosed 50 years later with idiopathic REM sleep behavior disorder and a history of sleepwalking. Clin. Neurol. Neurosurg. 160, 105–107 (2017).

  163. 163.

    Dugger, B. N. et al. Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov. Disord. 27, 72–78 (2012).

  164. 164.

    Fereshtehnejad, S.-M., Zeighami, Y., Dagher, A. & Postuma, R. B. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain 140, 1959–1976 (2017).

  165. 165.

    Zhou, J. et al. Mortality and its risk factors in patients with rapid eye movement sleep behavior disorder. Sleep 39, 1543–1550 (2016).

  166. 166.

    Boeve, B. F. et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 14, 754–762 (2013). This is the largest series of PSG-confirmed and probable RBD cases undergoing autopsy and shows a strong association of RBD with α-synucleinopathies.

  167. 167.

    McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88–100 (2017).

  168. 168.

    Berg, D. et al. MDS research criteria for prodromal Parkinson’s disease. Mov. Disord. 30, 1600–1611 (2015).

  169. 169.

    Postuma, R. B., Gagnon, J.-F., Vendette, M., Desjardins, C. & Montplaisir, J. Y. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann. Neurol. 69, 811–818 (2011).

  170. 170.

    Postuma, R. B., Gagnon, J.-F., Bertrand, J.-A., Marchand, D. G. & Montplaisir, J. Y. Parkinson risk in idiopathic REM sleep behavior disorder Preparing for neuroprotective trials. Neurology 84, 1104–1113 (2015).

  171. 171.

    Postuma, R. B., Gagnon, J.-F., Pelletier, A. & Montplaisir, J. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Mov. Disord. 28, 597–604 (2013).

  172. 172.

    Postuma, R. B., Lanfranchi, P. A., Blais, H., Gagnon, J.-F. & Montplaisir, J. Y. Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov. Disord. 25, 2304–2310 (2010).

  173. 173.

    Leclair-Visonneau, L. et al. REM sleep behavior disorder is related to enteric neuropathology in Parkinson disease. Neurology 89, 1612–1618 (2017).

  174. 174.

    Postuma, R. B., Lang, A. E., Gagnon, J. F., Pelletier, A. & Montplaisir, J. Y. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 135, 1860–1870 (2012).

  175. 175.

    Marchand, D. G., Montplaisir, J., Postuma, R. B., Rahayel, S. & Gagnon, J.-F. Detecting the cognitive prodrome of dementia with Lewy bodies: a prospective study of REM sleep behavior disorder. Sleep 40, zsw014 (2017).

  176. 176.

    Iranzo, A., Serradell, M. & Santamaria, J. Excessive daytime sleepiness does not predict neurodegeneration in idiopathic REM sleep behavior disorder. Sleep 40, zsx161 (2017).

  177. 177.

    Postuma, R. B., Gagnon, J.-F., Pelletier, A. & Montplaisir, J. Y. Insomnia and somnolence in idiopathic RBD: a prospective cohort study. NPJ Park. Dis. 3, 1 (2017).

  178. 178.

    Postuma, R. B., Gagnon, J.-F., Rompré, S. & Montplaisir, J. Y. Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology 74, 239–244 (2010).

  179. 179.

    Postuma, R. B. et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep 36, 1579–1585 (2013).

  180. 180.

    Heller, J. et al. Brain imaging findings in idiopathic REM sleep behavior disorder (RBD)–A systematic review on potential biomarkers for neurodegeneration. Sleep Med. Rev. 34, 23–33 (2017).

  181. 181.

    Eisensehr, I. et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder: comparison with Parkinson’s disease and controls. Brain 123, 1155–1160 (2000).

  182. 182.

    Eisensehr, I. et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson’s disease, and controls. Sleep 26, 507–512 (2003).

  183. 183.

    Iranzo, A. et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 10, 797–805 (2011).

  184. 184.

    Iranzo, A. et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 9, 1070–1077 (2010).

  185. 185.

    Iranzo, A. et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol. 82, 419–428 (2017).

  186. 186.

    Holtbernd, F. et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 82, 620–627 (2014).

  187. 187.

    Wu, P. et al. Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain 137, 3122–3128 (2014).

  188. 188.

    Sommerauer, M. et al. Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain 141, 496–504 (2017).

  189. 189.

    Knudsen, K. et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 17, 618–628 (2018).

  190. 190.

    Stokholm, M. G. et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 16, 789–796 (2017).

  191. 191.

    Dang-Vu, T. T. et al. Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder. Neurology 79, 2302–2306 (2012).

  192. 192.

    Iranzo, A. et al. Electroencephalographic slowing heralds mild cognitive impairment in idiopathic REM sleep behavior disorder. Sleep Med. 11, 534–539 (2010).

  193. 193.

    Brazète, J. R. et al. Electroencephalogram slowing predicts neurodegeneration in rapid eye movement sleep behavior disorder. Neurobiol. Aging 37, 74–81 (2016).

  194. 194.

    Iranzo, A. et al. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. Mov. Disord. 29, 1774–1780 (2014).

  195. 195.

    Rolinski, M. et al. Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson’s disease. Brain 139, 2224–2234 (2016).

  196. 196.

    Pyatigorskaya, N. et al. Magnetic resonance imaging biomarkers to assess substantia nigra damage in idiopathic rapid eye movement sleep behavior disorder. Sleep 40, zsx149 (2017).

  197. 197.

    Sprenger, F. S. et al. Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology 85, 1761–1768 (2015).

  198. 198.

    Doppler, K. et al. Dermal phospho-α-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol. 133, 535–545 (2017).

  199. 199.

    Antelmi, E., Donadio, V., Incensi, A., Plazzi, G. & Liguori, R. Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder. Neurology 88, 2128–2131 (2017).

  200. 200.

    Vilas, D. et al. Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 15, 708–718 (2016). This is the first study to show the presence of aggregates of phosphorylated α-synuclein within the submandibular gland biopsy in patients with PSG-confirmed iRBD.

  201. 201.

    Goldman, J. G. & Postuma, R. Premotor and non-motor features of Parkinson’s disease. Curr. Opin. Neurol. 27, 434–441 (2014).

  202. 202.

    Postuma, R. B. & Berg, D. Advances in markers of prodromal Parkinson disease. Nat. Rev. Neurol. 12, 622–634 (2016).

  203. 203.

    Arnaldi, D., Antelmi, E., Louis, E. K. S., Postuma, R. B. & Arnulf, I. Idiopathic REM sleep behavior disorder and neurodegenerative risk: to tell or not to tell to the patient? How to minimize the risk? Sleep Med. Rev. 36, 82–95 (2017).

  204. 204.

    Kornum, B. R. et al. Narcolepsy. Nat. Rev. Dis. Primer 3, 16100 (2017).

  205. 205.

    Mayer, G. Efficacy of sodium oxybate on REM sleep behavior disorder in a patient with narcolepsy type 1. Neurology 87, 2594–2595 (2016).

  206. 206.

    Barateau, L., Lopez, R. & Dauvilliers, Y. Treatment options for narcolepsy. CNS Drugs 30, 369–379 (2016).

  207. 207.

    Antelmi, E. et al. The spectrum of REM sleep-related episodes in children with type 1 narcolepsy. Brain 140, 1669–1679 (2017).

  208. 208.

    Nevsimalova, S., Prihodova, I., Kemlink, D., Lin, L. & Mignot, E. REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. Sleep Med. 8, 784–786 (2007).

  209. 209.

    Gagnon, J. F. et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology 59, 585–589 (2002).

  210. 210.

    Plazzi, G. et al. REM sleep behavior disorders in multiple system atrophy. Neurology 48, 1094–1096 (1997).

  211. 211.

    Lam, S. P., Fong, S. Y., Ho, C. K., Yu, M. W. & Wing, Y. K. Parasomnia among psychiatric outpatients: a clinical, epidemiologic, cross-sectional study. J. Clin. Psychiatry 69, 1374–1382 (2008).

  212. 212.

    Ju, Y.-E., Larson-Prior, L. & Duntley, S. RBD and antidepressants. Sleep Med. 13, 211–212 (2012).

  213. 213.

    Ju, Y.-E., Larson-Prior, L. & Duntley, S. Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants. Sleep Med. 12, 278–283 (2011).

  214. 214.

    St Louis, E. K. & Boeve, B. F. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin. Proc. 92, 1723–1736 (2017).

Download references

Acknowledgements

The authors thank R. Lopez for assisting with the reference management.

Reviewer information

Nature Reviews Disease Primers thanks C. Bassetti, Y. Wing and the other anonymous referee(s) for their contribution to the peer review of this work.

Author information

Affiliations

  1. Centre National de Référence Narcolepsie Hypersomnies, Unité des Troubles du Sommeil, Service de Neurologie, Hôpital Gui-de-Chauliac Montpellier, Montpellier, France

    • Yves Dauvilliers
  2. INSERM, U1061, Montpellier, France, Université Montpellier, Montpellier, France

    • Yves Dauvilliers
  3. Minnesota Regional Sleep Disorders Center, and Departments of Psychiatry, Hennepin County Medical Center and University of Minnesota Medical School, Minneapolis, MN, USA

    • Carlos H. Schenck
  4. Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada

    • Ronald B. Postuma
  5. Neurology Service, Multidisciplinary Sleep Unit, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain

    • Alex Iranzo
  6. UMR 5292 CNRS/U1028 INSERM, Center of Research in Neuroscience of Lyon (CRNL), SLEEP Team, Université Claude Bernard Lyon I, Faculté de Médecine RTH Laennec, Lyon, France

    • Pierre-Herve Luppi
  7. Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy

    • Giuseppe Plazzi
  8. IRCCS, Istituto delle Scienze Neurologiche, Bologna, Italy

    • Giuseppe Plazzi
  9. Department of Psychiatry, Université de Montréal, Québec, Canada and Center for Advanced Research in Sleep Medicine (CARSM), Hôpital du Sacré-Coeur de Montréal, Quebec, Canada

    • Jacques Montplaisir
  10. Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, MN, USA

    • Bradley Boeve

Authors

  1. Search for Yves Dauvilliers in:

  2. Search for Carlos H. Schenck in:

  3. Search for Ronald B. Postuma in:

  4. Search for Alex Iranzo in:

  5. Search for Pierre-Herve Luppi in:

  6. Search for Giuseppe Plazzi in:

  7. Search for Jacques Montplaisir in:

  8. Search for Bradley Boeve in:

Contributions

Introduction (Y.D. and C.H.S.); Epidemiology (B.B. and R.B.P.); Mechanisms/pathophysiology (A.I. and P.-H.L.); Diagnosis, screening and prevention (G.P., J.M. and Y.D.); Management (B.B. and A.I.); Quality of life (C.H.S. and G.P.); Outlook (R.B.P. and Y.D.); Overview of Primer (Y.D.).

Competing interests

Y.D. has consulted for UCB Pharma, Jazz, Theranexus, Flamel, Idorsia, Takeda, Harmony Biosciences and Bioprojet. C.H.S. is a Consultant for Axovant Sciences, Inc. R.B.P. reports grants and personal fees from Fonds de la Recherche en Sante, the Canadian Institute of Health Research, Parkinson Canada, the Garfield Weston Foundation, the Michael J. Fox Foundation and the Webster Foundation and personal fees from Biotie, Roche/Prothena, Takeda, Teva Neurosciences, AbbVie, Novartis, Janssen, Jazz Pharmaceuticals, Biogen, Boehringer Ingelheim, Theranexus and GE HealthCare outside the submitted work. G.P. participated in advisory boards for Jazz Pharmaceuticals, UCB Pharma and Bioprojet. J.M. received an honorarium to participate in advisory boards for Merck, Novartis and Takeda pharmaceuticals. B.B. has served as an investigator for clinical trials sponsored by GE Healthcare and Axovant, receives royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009, 2017) and serves on the Scientific Advisory Board of the Tau Consortium. B.B. also receives research support from the NIH (U01 AG045390, U54 NS092089, P50 AG016574, UO1 AG006786 and RO1 AG041797), the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and the Little Family Foundation. All other authors declare no competing interests.

Corresponding author

Correspondence to Yves Dauvilliers.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41572-018-0016-5